Keith Fandrick

Keith Fandrick, Ph.D. is the Chief Development Officer for AI Therapeutics. Dr. Fandrick graduated with his Ph.D. in Chemistry from Harvard under the guidance of Professor David Evans where he worked on novel asymmetric methodologies and asymmetric synthesis of complex natural products. After graduation, he joined the Chemical Development group at Boehringer Ingelheim where he was charged with the development of the safe, economical, and robust asymmetric synthesis of challenging compounds. His background and experience also include computational modeling with Quantum Mechanical/Density Function Theory. Dr. Fandrick has over 70 publications and patents and currently serves as the Head of Chemistry and CMC at AI Therapeutics.